[Cyclodestructive procedures in secondary glaucoma in children]

Bronisława Koraszewska-Matuszewska1, Rafał Leszczyński, Elzbieta Samochowiec-Donocik

  • 1Kliniki Okulistyki Dzieciecej Slaskiej Akademii Medycznej w Katowicach.

Klinika Oczna
|October 30, 2004
PubMed

Insights

Transscleral contact cyclophotocoagulation with diode laser (TSCPC) is more effective than cyclocryocoagulation for lowering intraocular pressure in children. However, TSCPC is associated with more severe complications than cyclocryocoagulation.

Area of Science:

  • Ophthalmology
  • Pediatric Ophthalmology

Background:

  • Pediatric glaucoma management often requires interventions to control intraocular pressure (IOP).
  • Cyclodestructive procedures are utilized when other treatments fail.
  • Comparison of cyclocryocoagulation and transscleral contact cyclophotocoagulation (TSCPC) in pediatric populations is crucial for treatment selection.

Purpose of the Study:

  • To compare the effectiveness and safety of cyclocryocoagulation versus diode laser transscleral contact cyclophotocoagulation (TSCPC) in pediatric patients.
  • To evaluate intraocular pressure (IOP) reduction and complication rates for both procedures.

Main Methods:

  • Sixty-nine eyes of 60 children (4 months to 16 years) underwent either cyclocryotherapy (40 eyes) or TSCPC (29 eyes).
  • Patients included those aphakic post-cataract extraction, with aniridia, Sturge-Weber disease, or ROP complications.
  • Intraocular pressure (IOP), visual acuity, and complications were assessed in early and late postoperative periods with a mean follow-up of 23 months.

Main Results:

  • TSCPC required fewer procedures per eye (1.14) compared to cyclocryotherapy (1.3).
  • IOP reduction was significantly greater with TSCPC (57.9% of eyes) than cyclocryotherapy (39% of eyes) (p=0.0003).
  • Long-term IOP below 22 mmHg was achieved in 79% of eyes after TSCPC versus 60% after cyclocryotherapy; however, TSCPC had more severe complications including uveitis and transient hypotony.

Conclusions:

  • Diode laser TSCPC demonstrates superior efficacy in lowering IOP in children compared to cyclocryocoagulation.
  • While effective, TSCPC is associated with a higher incidence of more severe complications than cyclocryotherapy.
  • Treatment choice requires careful consideration of efficacy versus potential adverse events in pediatric glaucoma management.
Abstract

Related Concept Videos

Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...